求DOF期刊2018年10-12期文獻(xiàn)   [更多]

1、 Development and validation of RP-HPLC method for simultaneous estimation of Ofloxacin and Ornidazole inpresence of Ornidazole Impurity in combined pharmaceutical dosage form 2、 Minerva Gastroenterol Dietol. 2015 Dec;61(4):273-92. Probiotics in digestive diseases: focus on Lactobacillus GG. Pace F1, Pace M, Quartarone G. 3、 El-Safory N S，F(xiàn)azary A E，Lee C-K. Hyaluronidases, a group of glycosidases: current and future perspectives[J]. Carbohydrate Polymers, 2010, 81(2): 165-181. 4、 Perng CK, Wang YJ, Tsi CH，et al. In vivo angiogenesis effect of porous collagen scaffold with hyaluronic acid oligosaccharides. J Surg Res，2011，168(1) : 9-15. 5、 Termeer C, Sleeman JP, Simon JC. Hyaluronan- magic glue for the regulation of the immune response [J]. Trends Immunol, 2003, 24(3):112- 114. 6、 https://www.eurekalert.org/pub_releases/2019-01/uob-bri010819.php 7、 Collection of Czechoslovak Chmical Communication, 1987, vol47, #1, P65-71. 8、 Phloroglucinol in irritable bowel syndrome 9、 Phosphodiesterase 5 inhibitors in male sexual dysfunction 10、 The Response to Vedolizumab in Chronic Granulomatous Disease   [更多]

標(biāo)題：重金求購(gòu)“DTaP/IPV”《 BP2015 》的藥典標(biāo)準(zhǔn)一份. 詳細(xì)要求： 需求名稱：Diphtheria, Tetanus, Pertussis (Acellular Component) and Inactivated Poliomyelitis Vaccine, Adsorbed的藥典標(biāo)準(zhǔn) 具體要求：英文原文電子版，最好有中文 要求時(shí)間：請(qǐng)?jiān)?019年1月22日之前 交稿方式：直接點(diǎn)擊交稿在線交稿就是了，我會(huì)每天過(guò)來(lái)看的，謝謝各位藥智的戰(zhàn)友們   [更多]

求購(gòu)：USP Monographs: Temozolomide for Injection”《 USP41-NF36 》的美國(guó)藥典（USP41-NF36 ）標(biāo)準(zhǔn)一份   [更多]

求購(gòu)“USP Monographs: Teriparatide Injection”《 USP41-NF36 》的藥典標(biāo)準(zhǔn)一份.   [更多]

“Formulated Preparations: Specific Monographs: Inositol Nicotinate Tablets”《 BP2019 》的藥典標(biāo)準(zhǔn)一份.   [更多]

最好能附帶原料藥標(biāo)準(zhǔn)   [更多]

1. Miller J. Ogidigben, Teh-Ching Chu and David E. Potter. Naphazoline-induced neuroendocrine changes Increases in ANP and cGMP levels 2. Robert J. Dockhorn and Thomas G. Duckett. Comparison of Naphcon-A and Its components 3. Mark B, Abelson MD, Salim I, et al. Tolerance and absence of rebound vasodilation following topical ocular decongestant usage 4. Ogidigben MJ, Chu TC, Potter DE. Naphazoline-induced suppression of aqueous humor pressure and flowinvolvement of central and peripheral alpha(2) I(1) receptors 5. The efficacy of long-term treatment with Tolvaptan to prolong the time until dialysis initiation in patients with chronic kidney disease and heart failure 6. Renoprotective effects of tolvaptan in hypertensive heart failure rats depend on renal decongestion 7. Tolvaptan Efficiently Reduces Intracellular Fluid Working Toward a Potential Treatment Option for Cellular Edema 8. Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites 9. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease 10. Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement 11. Nephrol Dial Transplant. 2018 Oct 12. doi 10.1093ndtgfy297. [Epub ahead of print] 12. Nephrol Dial Transplant. 2018 Oct 11. doi 10.1093ndtgfy298. [Epub ahead of print] 13. Development and validation of RP-HPLC method for simultaneous estimation of Ofloxacin and Ornidazole inpresence of Ornidazole Impurity in combined pharmaceutical dosage form 14. Stability-indicating methods for the determination of Ornidazole in the presence of its degradate according to ICH guidelines 15. A sensitive HPLC method of determination of 2-methyl 5-nitro imidazole & reaction mass of intermediates of ornidazole in ornidazole bulk manufacturing 16. Development and validation of a reversed-phase HPLC method for the analysis of ornidazole in pharmaceutical dosage forms 17. On the hydrolytic behavior of tinidazole, metronidazole,   [更多]

1.Bulletin of the Chemical Society of Japan, Volume 26, Pages 119-122, Journal, 1953 2.Dalton Transactions 2017,vol. 46, # 5, p. 1510 - 1519 3.Design and evaluation of ophthalmic pharmaceutical products. In Banker GS, Rhodes CT, eds. Modern Pharmaceutics, 4th edn. New York Marcel Dekker, 2002 415-478 4.Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer 5.Journal of Photochemistry and Photobiology, B Biology, Volume 97, Issue 1, Pages 18-21, Journal, 2009 6.Journal of Photochemistry and Photobiology, B Biology, Volume 115, Pages 51-57, Journal; Online Computer File, 2012 7.Nair AD, Lach JL. The kinetics of degradation of chlorobutanol. J Am Pharm Assoc (Sci) 1959; 48 390-395. 8.Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine 9.Plasma?renin?activity-guided strategy for the management of hypertension. 10.Stability of chlorobutanol in aqueous solutions Journal of the American Pharmaceutical Association (1961), Volume 6, Issue 7, July 1966, Pages 372-373 11.Talanta, Volume 146, Pages 732-736, Journal; Online Computer File, 2016   [更多]

需要Furazolidone《 BP2019 》的電子版本。   [更多]